» Articles » PMID: 27752240

Mastocytosis and Systemic Sclerosis: a Clinical Association

Overview
Publisher Biomed Central
Date 2016 Oct 19
PMID 27752240
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by vascular alterations and autoimmune activation leading to widespread organ fibrosis. At the early stage of disease when organ involvement and extent of disease are emerging, mast cells may have some role, as implied by both symptoms and histologic evidence.

Case Presentation: A female patient diagnosed with cutaneous mastocytosis experienced the onset of systemic sclerosis after 15 years followed by the switch of mastocytosis to the systemic phenotype. A literature review on the evidences related to mast-cells activation in systemic sclerosis is presented below.

Conclusions: For clinicians, more attention must be paid to the potential association between systemic sclerosis and cancer. This case suggests that a proliferative disease in the mast cell compartment-though representing a rare association-may not be completely unexpected in SSc and perhaps excess mast cell activity can serve a pathogenic role in promoting fibrotic disease.

Citing Articles

Molecular Mechanisms Behind the Role of Plasmacytoid Dendritic Cells in Systemic Sclerosis.

Silva I, Ferreira B, Almeida C Biology (Basel). 2023; 12(2).

PMID: 36829561 PMC: 9953616. DOI: 10.3390/biology12020285.


Immune cell dysregulation as a mediator of fibrosis in systemic sclerosis.

Fang D, Chen B, Lescoat A, Khanna D, Mu R Nat Rev Rheumatol. 2022; 18(12):683-693.

PMID: 36352098 DOI: 10.1038/s41584-022-00864-7.


Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis.

Papadimitriou T, van Caam A, van der Kraan P, Thurlings R Biomedicines. 2022; 10(2).

PMID: 35203525 PMC: 8869277. DOI: 10.3390/biomedicines10020316.


The Epithelial-to-Mesenchymal Transition as a Possible Therapeutic Target in Fibrotic Disorders.

Di Gregorio J, Robuffo I, Spalletta S, Giambuzzi G, De Iuliis V, Toniato E Front Cell Dev Biol. 2021; 8:607483.

PMID: 33409282 PMC: 7779530. DOI: 10.3389/fcell.2020.607483.


The immunopathogenesis of fibrosis in systemic sclerosis.

Brown M, OReilly S Clin Exp Immunol. 2018; 195(3):310-321.

PMID: 30430560 PMC: 6378383. DOI: 10.1111/cei.13238.

References
1.
Razykov I, Thombs B, Hudson M, Bassel M, Baron M . Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Rheum. 2009; 61(12):1765-70. DOI: 10.1002/art.25010. View

2.
Onishi A, Sugiyama D, Kumagai S, Morinobu A . Cancer incidence in systemic sclerosis: meta-analysis of population-based cohort studies. Arthritis Rheum. 2013; 65(7):1913-21. DOI: 10.1002/art.37969. View

3.
Frigui M, Dupin N, Carlotti A, Bussone G, Pestre V, Charles P . Telangiectasic mastocytosis with systemic sclerosis. Presse Med. 2012; 42(5):902-4. DOI: 10.1016/j.lpm.2012.10.014. View

4.
Bagnato G, Harari S . Cellular interactions in the pathogenesis of interstitial lung diseases. Eur Respir Rev. 2015; 24(135):102-14. PMC: 9487765. DOI: 10.1183/09059180.00003214. View

5.
Steen V . Clinical manifestations of systemic sclerosis. Semin Cutan Med Surg. 1998; 17(1):48-54. DOI: 10.1016/s1085-5629(98)80062-x. View